



# Obstetric Critical Care Symposium

Saturday, April 11, 2026  
Dallas, Texas

## Breathing for Two

VV ECMO Support in Pregnancy

**UTSouthwestern**  
Medical Center

# Objectives

---

- Explain maternal and fetal considerations in patient selection for ECMO.
- Review risks and complications of ECMO that are unique to or amplified in pregnant postpartum patients.

# Case Presentation

---

A 24-year-old G1P0 woman with a past medical history of severe asthma at 26w gestational age presents with a severe asthma exacerbation. She has perioral cyanosis with minimal air movement, which does not improve after continuous bronchodilator therapy and NIPPV. She is intubated and started on continuous neuromuscular blockade and bronchodilators. Despite optimal ventilator management, the patient remains acidemic (pH 7.18) with elevated pCO<sub>2</sub>; plateau pressures are 32 cmH<sub>2</sub>O.

# Case Presentation

---

A 32-year-old G3P2 woman with a past medical history of diet-controlled diabetes at 28w gestational age presents with acute hypoxic respiratory failure secondary to influenza B. Saturations remain ~85% on maximal heated high-flow oxygen support and the patient is unable to tolerate NIPPV due to nausea and retching. She is intubated, placed on 6 mL/kg IBW tidal volumes, optimal PEEP for body habitus, neuromuscular blockade, and in prone position. Despite these interventions, ABG is 7.30/52/60.

# Patient Selection for VV ECMO in Pregnancy

---

- Indications for VV ECMO in pregnancy similar to general population
  - Multidisciplinary discussion paramount
  - Suggested modified criteria
    - PaCO<sub>2</sub> >50 mmHg (vs >60 mmHg)
    - Plateau pressure >30 cmH<sub>2</sub>O (vs >32 cmH<sub>2</sub>O)
- Contraindications unchanged

# Physiologic Changes in Pregnancy Relevant to ECMO

System	Parameter	Normal nonpregnant	Normal pregnant	Relevance to ECMO
Respiratory	pH	7.35 – 7.45	7.40 – 7.45	Target higher pH and lower PaCO <sub>2</sub> by adjusting sweep gas flow on ECMO
	PaCO <sub>2</sub>	35 – 45 mmHg	28 – 32 mmHg	
	PaO <sub>2</sub>	80 – 100 mmHg	100 – 110 mmHg	
	HCO <sub>3</sub> <sup>-</sup>	22 – 26 mEq/L	18 – 21 mEq/L	Reduced bicarbonate limits buffering capacity
Cardiovascular	Cardiac output	4 – 6 L/min	↑ 30% – 50%	Higher ECMO flow rates needed to ensure adequate maternal-fetal perfusion
	Heart rate	60 – 100 bpm	80 – 100 bpm	Recognize higher heart rate as normal
Mechanical	Aortocaval compression	None	Present after 20w gestational age	Compression can affect femoral cannulation and flows during support

# Physiologic Changes in Pregnancy Relevant to ECMO

System	Parameter	Normal nonpregnant	Normal pregnant	Relevance to ECMO
Respiratory	pH	7.35 – 7.45	7.40 – 7.45	Target higher pH and lower PaCO <sub>2</sub> by adjusting sweep gas flow on ECMO
	PaCO <sub>2</sub>	35 – 45 mmHg	28 – 32 mmHg	
	PaO <sub>2</sub>	80 – 100 mmHg	100 – 110 mmHg	
	HCO <sub>3</sub> <sup>-</sup>	22 – 26 mEq/L	18 – 21 mEq/L	Reduced bicarbonate limits buffering capacity
Cardiovascular	Cardiac output	4 – 6 L/min	↑ 30% – 50%	Higher ECMO flow rates needed to ensure adequate maternal-fetal perfusion
	Heart rate	60 – 100 bpm	80 – 100 bpm	Recognize higher heart rate as normal
Mechanical	Aortocaval compression	None	Present after 20w gestational age	Compression can affect femoral cannulation and flows during support

# Initiation of VV ECMO in Pregnancy

- Cannulation
  - Left uterine displacement may ease guidewire advancement
  - Consider fetal heart rate monitoring to monitor uterine blood flow
- Cardiovascular
  - Initial ECMO flows 5 – 6 L/m<sup>2</sup>/min
- Acid-base
  - Consider sodium bicarbonate infusion as temporizing measure



<https://doi.org/10.1155/2013/274814>

# ECMO Management Considerations in Pregnant Patients

System	Parameter	Target in nonpregnant patient	Considerations in pregnant patient
Cardiovascular	Cardiac output	Initial ECMO flow 3 – 4 L/m <sup>2</sup> /min	Initial ECMO flow 5 – 6 L/m <sup>2</sup> /min
	Heart rate		Conflicting recommendations re: beta-blockade

# ECMO Management Considerations in Pregnant Patients

System	Parameter	Target in nonpregnant patient	Considerations in pregnant patient
Cardiovascular	Cardiac output	Initial ECMO flow 3 – 4 L/m <sup>2</sup> /min	Initial ECMO flow 5 – 6 L/m <sup>2</sup> /min
	Heart rate		Conflicting recommendations re: beta-blockade
Respiratory	PaO <sub>2</sub>	Maintain 55 – 60 mmHg	Maintain >70 mmHg
	SpO <sub>2</sub>	Maintain >80%	Maintain >90%
	pH	Maintain >7.30	Maintain >7.40
	PaCO <sub>2</sub>	Maintain 35 – 45 mmHg	Maintain 28 – 32 mmHg
	HCO <sub>3</sub> <sup>-</sup>	Maintain 23 – 30 mmol/L	Maintain 18 – 21 mmol/L

# ECMO Management Considerations in Pregnant Patients

System	Parameter	Target in nonpregnant patient	Considerations in pregnant patient
Cardiovascular	Cardiac output	Initial ECMO flow 3 – 4 L/m <sup>2</sup> /min	Initial ECMO flow 5 – 6 L/m <sup>2</sup> /min
	Heart rate		Conflicting recommendations re: beta-blockade
Respiratory	PaO <sub>2</sub>	Maintain 55 – 60 mmHg	Maintain >70 mmHg
	SpO <sub>2</sub>	Maintain >80%	Maintain >90%
	pH	Maintain >7.30	Maintain >7.40
	PaCO <sub>2</sub>	Maintain 35 – 45 mmHg	Maintain 28 – 32 mmHg
	HCO <sub>3</sub> <sup>-</sup>	Maintain 23 – 30 mmol/L	Maintain 18 – 21 mmol/L
Renal	Creatinine		Lower baseline creatinine can mask early AKI
	eGFR		Increased eGFR alters drug clearance

# ECMO Management Considerations in Pregnant Patients

System	Parameter	Target in nonpregnant patient	Considerations in pregnant patient
Cardiovascular	Cardiac output	Initial ECMO flow 3 – 4 L/m <sup>2</sup> /min	Initial ECMO flow 5 – 6 L/m <sup>2</sup> /min
	Heart rate		Conflicting recommendations re: beta-blockade
Respiratory	PaO <sub>2</sub>	Maintain 55 – 60 mmHg	Maintain >70 mmHg
	SpO <sub>2</sub>	Maintain >80%	Maintain >90%
	pH	Maintain >7.30	Maintain >7.40
	PaCO <sub>2</sub>	Maintain 35 – 45 mmHg	Maintain 28 – 32 mmHg
	HCO <sub>3</sub> <sup>-</sup>	Maintain 23 – 30 mmol/L	Maintain 18 – 21 mmol/L
Renal	Creatinine		Lower baseline creatinine can mask early AKI
	eGFR		Increased eGFR alters drug clearance
Hematologic	Clotting factors, platelet function		Hypercoagulable state increases thrombosis risk

# Fetal Monitoring during VV ECMO

---

- Fetal well-being assessed by heart rate monitoring, ultrasound, umbilical artery Doppler velocimetry
- Nonreassuring tracings may indicate fetal hypoxia, hypercarbia, or uteroplacental insufficiency
  - Interpretation must also account for maternal sedation
- Frequency and method institution-dependent
  - Intermittent monitoring sufficient during pre-viability
  - Clinical scenario determines intermittent vs continuous monitoring post-viability

# Delivery Planning of Pregnant Patients on VV ECMO

---

- Decisions re: timing and mode of delivery must be individualized
- Routine delivery prior to 32 weeks may not have benefits
  - Studies show no improvement in respiratory parameters
  - Risks of iatrogenic prematurity
- Both vaginal and cesarean deliveries feasible
  - Cesarean deliveries associated with increased hemodynamic fluctuations, hemorrhage, infection
  - Vaginal delivery less predictable, lithotomy positioning may impede return

# Complications of VV ECMO in Pregnancy

---

- Maternal complications
  - Hemorrhage: surgical / procedural and nontraumatic
  - Venous thromboembolism
- Fetal complications
  - Preterm delivery
  - Fetal death

# Outcomes of VV ECMO in Pregnancy

---

- Maternal survival ~75%
  - Exceeds general adult population
- Fetal survival 55 – 100%
  - Mostly single-center case series
  - Systematic review aggregate fetal survival ~65%

# Case Presentation

---

A 24-year-old G1P0 woman with a past medical history of severe asthma at 26w gestational age presents with a severe asthma exacerbation. She has perioral cyanosis with minimal air movement, which does not improve after continuous bronchodilator therapy and NIPPV. She is intubated and started on continuous neuromuscular blockade and bronchodilators. Despite optimal ventilator management, the patient remains acidemic (pH 7.18) with elevated pCO<sub>2</sub>; plateau pressures are 32 cmH<sub>2</sub>O.

A 32-year-old G3P2 woman with a past medical history of diet-controlled diabetes at 24w gestational age presents with acute hypoxic respiratory failure secondary to influenza B. Saturations remain ~85% on maximal heated high-flow oxygen support and the patient is unable to tolerate NIPPV due to nausea and retching. She is intubated, placed on 6 mL/kg IBW tidal volumes, optimal PEEP for body habitus, neuromuscular blockade, and in prone position. Despite these interventions, ABG is 7.30/52/60.

# Case Questions

---

- Is VV ECMO indicated as a rescue therapy in these cases?
- Should the fetus be delivered prior to ECMO initiation?
- What are the goal pH, PaCO<sub>2</sub>, PaO<sub>2</sub>, and SpO<sub>2</sub> while on ECMO?
- What is the anticoagulation strategy in these cases?
- Should fetal monitoring be performed?
- What are the common complications of VV ECMO during pregnancy?
- How should next-of-kin be counseled regarding prognosis?

# Summary

---

- VV ECMO is a viable rescue therapy in pregnant women with respiratory failure refractory to standard treatments.
- Modified selection criteria should be considered (PaCO<sub>2</sub>, plateau pressures).
- Acid-base and oxygenation goals during VV ECMO should reflect physiologic demands of pregnancy (higher pH, PaO<sub>2</sub>, SpO<sub>2</sub>; lower PaCO<sub>2</sub>).
- Anticoagulation is not contraindicated but must be individualized.
- Fetal monitoring may be considered post-viability.
- Prior to 32w GA, delivery should be pursued for obstetric indications.
- Monitor closely for both hemorrhagic and thrombotic complications.
- Maternal and fetal prognoses are better than the general population.
- Robust multidisciplinary teamwork is necessary for success.

# References

---

- Agerstrand C, Abrams D, Biscotti M, Moroz L, Rosenzweig EB, D'Alton M, Brodie D, Bacchetta M. Extracorporeal Membrane Oxygenation for Cardiopulmonary Failure During Pregnancy and Postpartum. *Ann Thorac Surg*. 2016 Sep;102(3):774-779. doi: 10.1016/j.athoracsur.2016.03.005. Epub 2016 May 4. PMID: 27154158.
- Aissi James S, Guervilly C, Lesouhaitier M, Coppens A, Haddadi C, Lebreton G, Nizard J, Brechot N, Assouline B, Saura O, Levy D, Lefèvre L, Barhoum P, Chommeloux J, Hékimian G, Luyt CE, Kimmoun A, Combes A, Schmidt M. Delivery decision in pregnant women rescued by ECMO for severe ARDS: a retrospective multicenter cohort study. *Crit Care*. 2022 Oct 17;26(1):312. doi: 10.1186/s13054-022-04189-5. PMID: 36253839; PMCID: PMC9574812.
- Jeejeebhoy FM, Morrison LJ. Maternal cardiac arrest: a practical and comprehensive review. *Emerg Med Int*. 2013;2013:274814. doi: 10.1155/2013/274814. Epub 2013 Jul 17. PMID: 23956861; PMCID: PMC3730371.
- Lankford AS, Chow JH, Jackson AM, Wallis M, Galvagno SM Jr, Malinow AM, Turan OM, Menaker JA, Crimmins SD, Rector R, Kaczorowski D, Griffith B, Kon Z, Herr D, Mazzeffi MA. Clinical Outcomes of Pregnant and Postpartum Extracorporeal Membrane Oxygenation Patients. *Anesth Analg*. 2021 Mar 1;132(3):777-787. doi: 10.1213/ANE.0000000000005266. PMID: 33591093.
- Lu S, Zhang Y, Wei S, Li J, Li M, Ying J, Mu D, Shi Y, Li Y, Wu X. Extracorporeal membrane oxygenation in pregnancy and the post-partum period: a systematic review and meta-analysis. *J Matern Fetal Neonatal Med*. 2025 Dec;38(1):2457002. doi: 10.1080/14767058.2025.2457002. Epub 2025 Jan 29. PMID: 39880582.
- Naoum EE, O'Neil ER, Shamshirsaz AA. Extracorporeal membrane oxygenation (ECMO) in pregnancy and peripartum: a focused review. *Int J Obstet Anesth*. 2024 Nov;60:104247. doi: 10.1016/j.ijoa.2024.104247. Epub 2024 Aug 8. PMID: 39209576.
- Ripoll JG, Kahn-Pascual YO, Seelhammer TG, Bittner EA, Chang MG, Ortoleva J, Diaz Soto JC, Elmadhoun O, Naoum EE, Wieruszewski PM, Nabzdyk CG, Ramakrishna H. ECMO in Pregnancy: Analysis of Indications, Management and Outcomes. *J Cardiothorac Vasc Anesth*. 2025 Dec;39(12):3557-3575. doi: 10.1053/j.jvca.2025.08.030. Epub 2025 Aug 16. PMID: 40940245.
- Sebastian NA, Spence AR, Bouhadoun S, Abenhaim HA. Extracorporeal membrane oxygenation in pregnant and postpartum patients: a systematic review. *J Matern Fetal Neonatal Med*. 2022 Dec;35(24):4663-4673. doi: 10.1080/14767058.2020.1860932. Epub 2020 Dec 20. PMID: 33345652.
- Taha B, Guglielminotti J, Li G, Landau R. Utilization and Outcomes of Extracorporeal Membrane Oxygenation in Obstetric Patients in the United States, 1999-2014: A Retrospective Cross-Sectional Study. *Anesth Analg*. 2022 Aug 1;135(2):268-276. doi: 10.1213/ANE.0000000000005753. Epub 2021 Sep 13. PMID: 34724684.
- Wong, Michael J. MD\*; Bharadwaj, Shobana MBBS\*; Galey, Jessica L. MD\*; Lankford, Allison S. MD†; Galvagno, Samuel DO, PhD‡; Kodali, Bhavani Shankar MD\*. Extracorporeal Membrane Oxygenation for Pregnant and Postpartum Patients. *Anesthesia & Analgesia* 135(2):p 277-289, August 2022. | DOI: 10.1213/ANE.0000000000005861